The role of Ki-67 in Asian triple negative breast cancers: a novel combinatory panel approach

Tan, Ah-Hwee; Yeong, Joe; Lai, Chi-Kong; Ong, Chong Hui Clara; Lee, Bernett; Lim, Jeffrey Chun Tatt; Thike, Aye Aye; Iqbal, Jabed; Dent, Rebecca; Lim, Elaine; Tan, Puay Hoon

doi:10.1007/s00428-019-02635-4

Cited by 15 publications

(5 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, Yeong et al . [34, 114‐118] have previously used mIHC/IF to reveal the prognostic values of multiple tumor‐infiltrating lymphocyte (TIL) subsets in Asian triple negative breast cancer, such as FOXP3 + regulatory T cells (Treg), CD20 + B cells, CD38 + plasma cells, PD‐1 + CD8 + T cells and proliferating immune subsets. The quantitative approach of these works was convincingly validated with manual scoring by pathologists.…”

Section: Brightfield‐based Mihc/ifmentioning

confidence: 99%

Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy

Tan

Nerurkar

Cai

et al. 2020

Cancer Communications

Self Cite

439

318

View full text Add to dashboard Cite

Conventional immunohistochemistry (IHC) is a widely used diagnostic technique in tissue pathology. However, this technique is associated with a number of limitations, including high inter-observer variability and the capacity to label only one marker per tissue section. This review details various highly multiplexed techniques that have emerged to circumvent these constraints, allowing simultaneous detection of multiple markers on a single tissue section and the comprehensive study of cell composition, cellular functional and cell-cell interactions. Among these techniques, multiplex Immunohistochemistry/Immunofluorescence (mIHC/IF) has emerged to be particularly promising. mIHC/IF provides high-throughput multiplex staining and standardized quantitative analysis for highly reproducible, efficient and cost-effective tissue studies. This technique has immediate potential for translational research and clinical practice, particularly in the era of cancer immunotherapy.

show abstract

Section: Brightfield‐based Mihc/ifmentioning

confidence: 99%

Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy

Tan

Nerurkar

Cai

et al. 2020

Cancer Communications

Self Cite

439

318

View full text Add to dashboard Cite

show abstract

“…However, although Ki-67/PD-L1 labelling is useful by itself, a multiplex approach enables several markers to be interrogated simultaneously (Table 2). Both Tan et al 138 and our laboratory 105 exemplified this approach with mIHC/IF to stain a single tissue section with markers including CD8, PD-1, PD-L1, Ki-67 and cytokeratin to study their co-localisation in the inForm software (Figure 5). Digital pathology software can also help to score TILs in breast cancer in line with the proposed guidelines developed by the International TILs working group (Table 4).…”

Section: Mihc/if Can Be Fully Automatedmentioning

confidence: 99%

Delineating the breast cancer immune microenvironment in the era of multiplex immunohistochemistry/immunofluorescence

et al. 2021

Self Cite

View full text Add to dashboard Cite

Delineating the breast cancer immune microenvironment in the era of multiplex immunohistochemistry/immunofluorescence Breast cancer is the most common malignancy and the leading cause of cancer death in females worldwide. Treatment is challenging, especially for those who are triple-negative. Increasing evidence suggests that diverse immune populations are present in the breast tumour microenvironment, which opens up avenues for personalised drug targets. Historically, our investigations into the immune constitution of breast tumours have been restricted to analyses of one or two markers at a given time. Recent technological advances have allowed simultaneous labelling of more than 35 markers and detailed profiling of tumour-immune infiltrates at the single-cell level, as well as determining the cellular composition and spatial analysis of the entire tumour architecture. In this review, we describe emerging technologies that have contributed to the field of breast cancer diagnosis, and discuss how to interpret the vast data sets obtained in order to effectively translate them for clinically relevant use.

show abstract

“…For example, although Ki-67/PD-L1 labeling is useful by itself, a multiplex approach enables several markers to be interrogated simultaneously [34][35][36]. However, only analytical digital pathology solutions for Ki67 and PD-L1 scoring are currently commercially available as listed in Table 1 [33,37].…”

Section: Use Of Mihc In Combination With Digital Pathologymentioning

confidence: 99%

Approaches for Handling Immunopathological and Clinical Data Using Deep Learning Methodology: Multiplex IHC/IF Data as a Paradigm

Goh¹,

Chua²,

Lee³

et al. 2021

Pathology - From Classics to Innovations

View full text Add to dashboard Cite

Recent advancements in deep learning based artificial intelligence have enabled us to analyse complex data in order to provide patients with improved cancer prognosis, which is an important goal in precision health medicine. In this chapter, we would be discussing how deep learning could be applied to clinical data and immunopathological images to accurately determine survival rate prediction for patients. Multiplex immunohistochemistry/immunofluorescence (mIHC/IF) is a relatively new technology for simultaneous detection of multiple specific proteins from a single tissue section. To adopt deep learning, we collected and pre-processed the clinical and mIHC/IF data from a group of patients into three branches of data. These data were subsequently used to train and validate a neural network. The specific process and our recommendations will be further discussed in this chapter. We believe that our work will help the community to better handle their data for AI implementation while improving its performance and accuracy.

show abstract

The role of Ki-67 in Asian triple negative breast cancers: a novel combinatory panel approach

Cited by 15 publications

References 93 publications

Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy

Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy

Delineating the breast cancer immune microenvironment in the era of multiplex immunohistochemistry/immunofluorescence

Approaches for Handling Immunopathological and Clinical Data Using Deep Learning Methodology: Multiplex IHC/IF Data as a Paradigm

Contact Info

Product

Resources

About